Clinical Trial Update: Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating the safety of low-dose pegylated liposomal doxorubicin in combination with peposertib for advanced sarcoma; currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dedifferentiated Liposarcoma
• Leiomyosarcoma
• Myxofibrosarcoma
• Soft Tissue Sarcoma
• Synovial Sarcoma
• Undifferentiated Pleomorphic Sarcoma

Drugs mentioned

• Doxil (liposomal doxorubicin)
• Peposertib (Peposertib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Metastatic Dedifferentiated Liposarcoma, Metastatic Leiomyosarcoma | Phase 1 | Status: RECRUITING